From: Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia
Tolvaptan (n = 169) | Placebo (n = 61) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
0 day | 4 days | 7 days | 3 months | 6 months | 0 day | 4 days | 7 days | 3 months | 6 months | |
Normal sodium, mmol/L (n) | 138.15 ± 2.58 (100) | 140.28 ± 3.07 (95) | 139.83 ± 3.32* (95) | 136.88 ± 5.09* (56) | 136.97 ± 6.92* (49) | 138.60 ± 2.24 (32) | 138.52 ± 2.39 (29) | 138.23 ± 2.16 (24) | 136.97 ± 4.18 (14) | 133.18 ± 9.31 (11) |
Mild hyponatremia, mmol/L (n) | 132.98 ± 1.31 (44) | 138.02 ± 3.11** (44) | 136.59 ± 3.51** (41) | 133.78 ± 4.13** (33) | 131.96 ± 5.29** (23) | 131.96 ± 1.44 (21) | 131.34 ± 3.03 (13) | 131.06 ± 4.65 (13) | 129.45 ± 6.66 (11) | 134.50 ± 6.20 (9) |
Middle hyponatremis, mmol/L (n) | 127.35 ± 1.17 (19) | 131.50 ± 2.85** (18) | 132.29 ± 2.87** (18) | 132.24 ± 5.71** (11) | 129.81 ± 7.02** (10) | 127.94 ± 0.92 (7) | 130.30 ± 3.82 (5) | 129.20 ± 10.32 (3) | 134.30 (2) | 139.30 (2) |
Severe hyponatremia, mmol/L (n) | 120.87 ± 3.33 (6) | 126.87 ± 7.05** (6) | 126.50 ± 6.61** (5) | 131.10 ± 6.15** (3) | 132.30 (2) | 124.80 (1) | ND | ND | ND | ND |